{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:36:28Z","timestamp":1782923788209,"version":"3.54.5"},"reference-count":100,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Neurodegenerative diseases are a diverse group of diseases characterized by a progressive loss of neurological function due to damage to nerve cells in the central nervous system. In recent years, there has been a worldwide increase in the expanding associated with increasing human life expectancy. Molecular mechanisms control many of the essential life processes of cells, such as replication, transcription, translation, protein synthesis and gene regulation. These are complex interactions that form the basis for understanding numerous processes in the organism and developing new diagnostic and therapeutic approaches. In the context of neurodegenerative diseases, molecular basis refers to changes at the molecular level that cause damage to or degeneration of nerve cells. These may include protein aggregates leading to pathological structures in brain cells, impaired protein transport in nerve cells, mitochondrial dysfunction, inflammatory processes or genetic mutations that impair nerve cell function. New medical therapies are based on these mechanisms and include gene therapies, reduction in inflammation and oxidative stress, and the use of miRNAs and regenerative medicine. The aim of this study was to bring together the current state of knowledge regarding selected neurodegenerative diseases, presenting the underlying molecular mechanisms involved, which could be potential targets for new forms of treatment.<\/jats:p>","DOI":"10.3390\/cimb46060325","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:29:47Z","timestamp":1717417787000},"page":"5436-5453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular Mechanisms in the Design of Novel Targeted Therapies for Neurodegenerative Diseases"],"prefix":"10.3390","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3742-0914","authenticated-orcid":false,"given":"Ilona","family":"Nowak","sequence":"first","affiliation":[{"name":"Silesia LabMed, Centre for Research and Implementation, Medical University of Silesia in Katowice, 18 Medykow Str., 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Pa\u017adzior","sequence":"additional","affiliation":[{"name":"Silesia LabMed, Centre for Research and Implementation, Medical University of Silesia in Katowice, 18 Medykow Str., 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sarna","sequence":"additional","affiliation":[{"name":"Silesia LabMed, Centre for Research and Implementation, Medical University of Silesia in Katowice, 18 Medykow Str., 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-3149","authenticated-orcid":false,"given":"Marcel","family":"Madej","sequence":"additional","affiliation":[{"name":"Silesia LabMed, Centre for Research and Implementation, Medical University of Silesia in Katowice, 18 Medykow Str., 40-752 Katowice, Poland"},{"name":"Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dugger, B.N., and Dickson, D.W. (2017). Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a028035"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/539179a","article-title":"Neurodegenerative Diseases","volume":"539","author":"Heemels","year":"2016","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2174\/1381612827666210608152745","article-title":"Neurodegenerative diseases: A multidisciplinary approach","volume":"27","author":"Lozano","year":"2021","journal-title":"CPD"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"815347","DOI":"10.3389\/fnagi.2022.815347","article-title":"Microglia polarization from M1 to M2 in neurodegenerative diseases","volume":"14","author":"Guo","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Agnello, L., and Ciaccio, M. (2022). Neurodegenerative diseases: From molecular basis to therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112854"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/0006-2952(75)90094-5","article-title":"Digitoxin metabolism by rat liver microsomes","volume":"24","author":"Schmoldt","year":"1975","journal-title":"Biochem. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.arr.2023.102070","article-title":"The blood-brain barrier, a key bridge to treat neurodegenerative diseases","volume":"91","author":"Hang","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nowak, I., Madej, M., Secemska, J., Sarna, R., and Strzalka-Mrozik, B. (2023). Virus-based biological systems as next-generation carriers for the therapy of central nervous system diseases. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071931"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/CON.0000000000000911","article-title":"Amyotrophic lateral sclerosis and other motor neuron diseases","volume":"26","author":"Quinn","year":"2020","journal-title":"CONTINUUM Lifelong Learn. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/21678421.2018.1476547","article-title":"Co-occurrence of MS and ALS: A clue in favor of common pathophysiological findings?","volume":"19","author":"Guennoc","year":"2018","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2174\/1568026620666200924114827","article-title":"Exploring multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) as neurodegenerative diseases and their treatments: A review study","volume":"20","author":"Deeb","year":"2020","journal-title":"CTMC"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/WCO.0000000000001094","article-title":"Biomarkers for amyotrophic lateral sclerosis","volume":"35","author":"Witzel","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/CON.0000000000001157","article-title":"Progressive multiple sclerosis","volume":"28","author":"Amezcua","year":"2022","journal-title":"CONTINUUM Lifelong Learn. Neurol."},{"key":"ref_15","first-page":"1613","article-title":"Amyotrophic lateral sclerosis (ALS)\u2014Diagnosis, course of disease and treatment options","volume":"146","author":"Meyer","year":"2021","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, X., Ji, Y., Wang, W., Zhang, L., Chen, Z., Yu, M., Shen, Y., Ding, F., Gu, X., and Sun, H. (2021). Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies. Antioxidants, 10.","DOI":"10.3390\/antiox10071012"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/WCO.0000000000001093","article-title":"Update on genetics of amyotrophic lateral sclerosis","volume":"35","author":"Brenner","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lastres-Becker, I., Porras, G., Arribas-Bl\u00e1zquez, M., Maestro, I., Borrego-Hern\u00e1ndez, D., Boya, P., Cerd\u00e1n, S., Garc\u00eda-Redondo, A., Mart\u00ednez, A., and Martin-Requero, \u00c1. (2021). Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063007"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: A clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajmg.b.31158","article-title":"Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis","volume":"156","author":"Ticozzi","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations","volume":"61","author":"Mackenzie","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1093\/brain\/awad120","article-title":"Genetic variability in sporadic amyotrophic lateral sclerosis","volume":"146","author":"Moisse","year":"2023","journal-title":"Brain"},{"key":"ref_24","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.W., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dilliott, A.A., Andary, C.M., Stoltz, M., Petropavlovskiy, A.A., Farhan, S.M.K., and Duennwald, M.L. (2022). DnaJC7 in amyotrophic lateral sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084076"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: A review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22155","DOI":"10.1038\/srep22155","article-title":"TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion","volume":"6","author":"Pokrishevsky","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature05934","article-title":"Generation of germline-competent induced pluripotent stem cells","volume":"448","author":"Okita","year":"2007","journal-title":"Nature"},{"key":"ref_29","first-page":"e33242","article-title":"An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11882-023-01102-0","article-title":"Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches","volume":"23","author":"Vasileiou","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e37297","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"key":"ref_32","first-page":"988","article-title":"Epidemiology and Pathophysiology of Multiple Sclerosis","volume":"28","author":"Ward","year":"2022","journal-title":"Continuum"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"ref_34","first-page":"1025","article-title":"Treatment of multiple sclerosis","volume":"28","author":"Cross","year":"2022","journal-title":"Continuum"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ene.15593","article-title":"Diagnosis and treatment of progressive multiple sclerosis: A position paper","volume":"30","author":"Pozzilli","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: A tale of two amytrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fucito, M., and Pieragostino, D. (2022). Molecular research in multiple sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052792"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5334\/jbsr.2588","article-title":"Alexander disease","volume":"105","author":"Hartog","year":"2021","journal-title":"J. Belg. Soc. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"723218","DOI":"10.3389\/fphar.2021.723218","article-title":"Beneficial effect of phenytoin and carbamazepine on GFAP gene expression and mutant GFAP folding in a cellular model of Alexander\u2019s disease","volume":"12","author":"Bachetti","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ymgme.2021.11.009","article-title":"Alexander disease evolution over time: Data from an Italian cohort of pediatric-onset patients","volume":"134","author":"Mura","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2329048X2110486","DOI":"10.1177\/2329048X211048614","article-title":"Neuropsychological functioning in Alexander disease: A case series","volume":"8","author":"Kirsch","year":"2021","journal-title":"Child Neurol. Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s00247-023-05710-w","article-title":"Fetal-onset Alexander disease with radiological-neuropathological correlation","volume":"53","author":"Devos","year":"2023","journal-title":"Pediatr. Radiol."},{"key":"ref_43","unstructured":"Kuhn, J., and Cascella, M. (2024). StatPearls, StatPearls Publishing."},{"key":"ref_44","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.W., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/humu.24008","article-title":"Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform","volume":"41","author":"Helman","year":"2020","journal-title":"Hum. Mutat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1242\/jcs.02339","article-title":"Alexander-disease mutation of GFAP causes filament disorganization and decreased solubility of GFAP","volume":"118","author":"Hsiao","year":"2005","journal-title":"J. Cell Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/504411","article-title":"The Alexander disease-causing glial fibrillary acidic protein mutant, R416W, accumulates into Rosenthal fibers by a pathway that involves filament aggregation and the association of alpha B-crystallin and HSP27","volume":"79","author":"Su","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s11689-019-9290-0","article-title":"Refining the concept of GFAP toxicity in Alexander disease","volume":"11","author":"Messing","year":"2019","journal-title":"J. Neurodev. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Viedma-Poyatos, \u00c1., Gonz\u00e1lez-Jim\u00e9nez, P., Pajares, M.A., and P\u00e9rez-Sala, D. (2022). Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress. Redox Biol., 55.","DOI":"10.1016\/j.redox.2022.102415"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1759091420981206","DOI":"10.1177\/1759091420981206","article-title":"Regulation of GFAP Expression","volume":"13","author":"Brenner","year":"2021","journal-title":"ASN Neuro"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.conb.2021.10.002","article-title":"Alexander disease: Models, mechanisms, and medicine","volume":"72","author":"Hagemann","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1759091420949680","DOI":"10.1177\/1759091420949680","article-title":"GFAP at 50","volume":"12","author":"Messing","year":"2020","journal-title":"ASN Neuro"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4103\/1673-5374.369097","article-title":"Alexander disease: The road ahead","volume":"18","author":"Pajares","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.stem.2018.07.009","article-title":"GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12974-021-02118-x","article-title":"Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes","volume":"18","author":"Boyd","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eabg4711","DOI":"10.1126\/scitranslmed.abg4711","article-title":"Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment","volume":"13","author":"Hagemann","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.25118","article-title":"Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease","volume":"83","author":"Hagemann","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1073\/pnas.93.13.6361","article-title":"Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology","volume":"93","author":"McCall","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/mrm.29917","article-title":"Quantitative diffusion imaging and genotype-by-sex interactions in a rat model of Alexander disease","volume":"91","author":"Stowe","year":"2024","journal-title":"Magn. Reson. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: The integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Jiang, A., Handley, R.R., Lehnert, K., and Snell, R.G. (2023). From pathogenesis to therapeutics: A review of 150 years of Huntington\u2019s disease research. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241613021"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","article-title":"Huntington\u2019s disease: Diagnosis and management","volume":"22","author":"Stoker","year":"2022","journal-title":"Pract. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Pellegrini, M., Bergonzoni, G., Perrone, F., Squitieri, F., and Biagioli, M. (2022). Current diagnostic methods and non-coding RNAs as possible biomarkers in Huntington\u2019s disease. Genes, 13.","DOI":"10.3390\/genes13112017"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JHD-200427","article-title":"Huntington\u2019s disease pathogenesis: Two sequential components","volume":"10","author":"Hong","year":"2021","journal-title":"JHD"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4103\/1673-5374.360289","article-title":"Mitochondria in Huntington\u2019s disease: Implications in pathogenesis and mitochondrial-targeted therapeutic strategies","volume":"18","author":"Jurcau","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e15851","DOI":"10.15252\/emmm.202215851","article-title":"Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington\u2019s disease","volume":"14","author":"Liu","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"105147","DOI":"10.1016\/j.neuint.2021.105147","article-title":"Mitophagy in Huntington\u2019s disease","volume":"149","year":"2021","journal-title":"Neurochem. Int."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Jurcau, A. (2022). Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061432"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Caron, N.S., Southwell, A.L., Brouwers, C.C., Cengio, L.D., Xie, Y., Black, H.F., Anderson, L.M., Ko, S., Zhu, X., and van Deventer, S.J. (2019). Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res., gkz976.","DOI":"10.1093\/nar\/gkz976"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 mediated therapeutic approach in Huntington\u2019s disease","volume":"60","author":"Alkanli","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101385","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington\u2019s disease","volume":"70","author":"Fields","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jurcau, A., and Jurcau, M.C. (2022). Therapeutic strategies in Huntington\u2019s disease: From genetic defect to gene therapy. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081895"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"705348","DOI":"10.3389\/fncel.2021.705348","article-title":"MicroRNAs in Huntington\u2019s disease: Diagnostic biomarkers or therapeutic agents?","volume":"15","author":"Dong","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Spronck, E., Vall\u00e8s, A., Lampen, M., Montenegro-Miranda, P., Keskin, S., Heijink, L., Evers, M., Petry, H., Deventer, S., and Konstantinova, P. (2021). Intrastriatal administration of AAV5-MiHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology. Brain Sci., 11.","DOI":"10.3390\/brainsci11020129"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/a-2042-2338","article-title":"Gentherapie der Huntington-krankheit [Gene therapy for Huntington disease]","volume":"91","author":"Falkenburger","year":"2023","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington\u2019s disease: Lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Seo, J.H., Shin, J.H., Lee, J., Kim, D., Hwang, H.-Y., Nam, B.-G., Lee, J., Kim, H.H., and Cho, S.-R. (2023). DNA Double-strand break-free CRISPR interference delays Huntington\u2019s disease progression in mice. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04829-8"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Oura, S., Noda, T., Morimura, N., Hitoshi, S., Nishimasu, H., Nagai, Y., Nureki, O., and Ikawa, M. (2021). Precise CAG repeat contraction in a Huntington\u2019s disease mouse model is enabled by gene editing with SpCas9-NG. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-02304-w"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yao, M., Jiang, L., Yu, Y., Cui, Y., Chen, Y., Zhou, D., Gao, F., and Mao, S. (2024). Optimized MLPA workflow for spinal muscular atrophy diagnosis: Identification of a novel variant, NC_000005.10:g.(70919941_70927324)del in isolated exon 1 of SMN1 gene through long-range PCR. BMC Neurol., 24.","DOI":"10.1186\/s12883-024-03592-5"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e200087","DOI":"10.1212\/NXG.0000000000200087","article-title":"Phenotype presentation and molecular diagnostic yield in non-5q spinal muscular atrophy","volume":"9","author":"Theuriet","year":"2023","journal-title":"Neurol. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Aasdev, A.R.S.S., Iyer, V.R., and Moharir, S.C. (2024). Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context. J. Biosci., 49.","DOI":"10.1007\/s12038-023-00412-9"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chen, T.H. (2020). New and developing therapies in spinal muscular atrophy: From genotype to phenotype to treatment and where do we stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093297"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Angilletta, I., Ferrante, R., Giansante, R., Lombardi, L., Babore, A., Dell\u2019Elice, A., Alessandrelli, E., Notarangelo, S., Ranaudo, M., and Palmarini, C. (2023). Spinal muscular atrophy: An evolving scenario through new perspectives in diagnosis and advances in therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914873"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Cort\u00e9s, A., Echeverr\u00eda-Garc\u00e9s, G., and Ramos-Medina, M.J. (2022). Molecular pathogenesis and new therapeutic dimensions for spinal muscular atrophy. Biology, 11.","DOI":"10.3390\/biology11060894"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y., and Awano, H. (2023). Spinal muscular atrophy: The past, present, and future of diagnosis and treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511939"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Babi\u0107, M., Banovi\u0107, M., Bere\u010di\u0107, I., Bani\u0107, T., Babi\u0107 Leko, M., Ulamec, M., Junakovi\u0107, A., Kopi\u0107, J., Serti\u0107, J., and Bari\u0161i\u0107, N. (2023). Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155060"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e8513","DOI":"10.1002\/ccr3.8513","article-title":"Spinal muscular atrophy type 1: A fatal case in a 1-year-old girl with delayed diagnosis","volume":"12","author":"Rizvi","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: Mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/01677063.2020.1853721","article-title":"A rapid molecular diagnostic method for spinal muscular atrophy","volume":"35","author":"Wang","year":"2021","journal-title":"J. Neurogenet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3233\/JND-221668","article-title":"Closing the gap\u2014Detection of 5q-spinal muscular atrophy by short-read next-generation sequencing and unexpected results in a diagnostic patient cohort","volume":"10","author":"Kleinle","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Theil, D., Valdez, R., Darribat, K., Doelemeyer, A., Sivasankaran, R., and Hartmann, A. (2021). Orally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogs. Biol. Open, 10.","DOI":"10.1242\/bio.058551"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26331055241233596","DOI":"10.1177\/26331055241233596","article-title":"Synergistic effect of an antisense oligonucleotide and small molecule on splicing correction of the spinal muscular atrophy gene","volume":"19","author":"Ottesen","year":"2024","journal-title":"Neurosci. Insights"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41467-024-46090-5","article-title":"Specificity, synergy, and mechanisms of splice-modifying drugs","volume":"15","author":"Ishigami","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_97","first-page":"e524","article-title":"Molecular biomarkers for spinal muscular atrophy: A systematic review","volume":"11","author":"Garrison","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Rech, J., Getinger-Panek, A., Ga\u0142ka, S., and Bednarek, I. (2022). Origin and composition of exosomes as crucial factors in designing drug delivery systems. Appl. Sci., 12.","DOI":"10.3390\/app122312259"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kurowska, N., Strzalka-Mrozik, B., Madej, M., Paj\u0105k, K., Kruszniewska-Rajs, C., Kaspera, W., and Gola, J.M. (2022). Differences in the expression patterns of TGF\u03b2 isoforms and associated genes in astrocytic brain tumors. Cancers, 14.","DOI":"10.3390\/cancers14081876"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e944204","DOI":"10.12659\/MSM.944204","article-title":"Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent \u03b2-Thalassemia","volume":"30","author":"Parums","year":"2024","journal-title":"Med. Sci. Monit."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/6\/325\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:18Z","timestamp":1760107818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/6\/325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":100,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cimb46060325"],"URL":"https:\/\/doi.org\/10.3390\/cimb46060325","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}